At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 151 enrolled
Drug / intervention
Follicle Stimulating Hormone +1 moredrug
Likely dose
Follicle Stimulating Hormone 225 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentric Prospective, Randomised, Controlled Clinical Study on Clinical Efficacy and Tolerability of Urinary FSH (Fostimon® , IBSA) Versus r-FSH (Gonal-F®, Serono) in ICSI.
In Brief
A Phase 3 clinical trial evaluating Follicle Stimulating Hormone for Infertility. Completed, enrolled 151 participants across 7 sites in 2 countries.
Detailed Summary
Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Serono) when administered in patients undergoing ICSI
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility
CountriesFrance, Hungary
Collaborators--
Timeline
Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2003
Primary CompletionDec 2005
First PostedJun 2006
TodayJul 2026
First PostedJun 12, 2006
Enrollment StartMar 1, 2003
Primary CompletionDec 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.1 years ago
Interventions
Follicle Stimulating Hormonedrug
subcutaneous injection of FSH. Starting dose: 225 IU.
Follicle Stimulating Hormonedrug
subcutaneous injection of FSH. Starting dose: 225 IU.